Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice.
The possibility that dietary vitamin D(3) (VD(3)) exposure inhibits endometrial carcinogenesis in an animal model and modifies the enhanced risk of endometrial carcinoma associated with obesity was investigated. At 4 weeks of age, Pten(+/-) and wild-type mice were each divided into four treatment groups and fed AIN93G control diet, or AIN93G-based diet containing either 25,000 international units of VD(3) per kilogram of diet, 58% fat to induce obesity (high fat), or high fat and 25,000 international units of VD(3) per kilogram of diet. Mice were kept on these diets until they were sacrificed at week 28. Although VD(3) did not affect endometrial cancer risk, it inhibited obesity-induced increase in endometrial lesions. Specifically, high-fat diet increased focal glandular hyperplasia with atypia and malignant lesions from 58% in the control diet-fed Pten(+/-) mice to 78% in obese mice. Dietary VD(3) decreased the incidence of endometrial pathology in obese Pten(+/-) mice to 25% (P < 0.001). VD(3) altered the endometrial expression of 25-hydroxylase, 1α-hydroxylase, and vitamin D receptor in the wild-type and Pten(+/-) mice. Estrogen receptor-α mRNA levels were higher (P < 0.014) and progesterone receptor protein levels in the luminal epithelium were lower (P < 0.04) in the endometrium of control diet-fed Pten(+/-) than wild-type mice, but the expression of these receptors was not affected by the dietary exposures. VD(3) reversed the obesity-induced increase in osteopontin (P < 0.001) and significantly increased E-cadherin expression (P < 0.019) in the endometrium of obese Pten(+/-) mice. Our data confirm the known association between obesity and endometrial cancer risk. Dietary exposure to VD(3) inhibited the carcinogenic effect of obesity on the endometrium. This protective effect was linked to a reduction in the expression of osteopontin and increase in E-cadherin.
Yu
Wei
W
Department of Oncology, Georgetown University, Washington, DC 20057, USA.
Cline
Mark
M
Maxwell
Larry G
LG
Berrigan
David
D
Rodriguez
Gustavo
G
Warri
Anni
A
Hilakivi-Clarke
Leena
L
D000818:Animals; D015153:Blotting, Western; D015519:Bone Density / Q000187:drug effects; D015820:Cadherins / Q000096:biosynthesis / Q000187:drug effects; D002762:Cholecalciferol / Q000008:administration & dosage*; D004032:Diet; D016889:Endometrial Neoplasms / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis; D005260:Female; D007150:Immunohistochemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D009765:Obesity / Q000150:complications*; D053495:Osteopontin / Q000096:biosynthesis / Q000187:drug effects; D051059:PTEN Phosphohydrolase / Q000235:genetics; D011230:Precancerous Conditions / Q000209:etiology / Q000473:pathology; D011980:Receptors, Progesterone / Q000096:biosynthesis
D015820:Cadherins; D047628:Estrogen Receptor alpha; D011980:Receptors, Progesterone; D053495:Osteopontin; D002762:Cholecalciferol; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse